Χώρα: Ισραήλ
Γλώσσα: Αγγλικά
Πηγή: Ministry of Health
BRIGATINIB
TAKEDA ISRAEL LTD
L01XE43
FILM COATED TABLETS
BRIGATINIB 90 MG
PER OS
Required
TAKEDA PHARMA A/S, DENMARK
BRIGATINIB
ALUNBRIG is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)
2023-10-31
TAKEDA ISRAEL LTD. 25 Efal st., P.O.B 4140, Petach-Tikva 4951125 Tel:+972-3-3733140 Fax (local) : + 972-3-3733150 18.5.2023 / , / / , : ( 35334 ) ALUNBRIG 30 MG ALUNBRIG 90 MG (35335) FILM COATED TABLETS " . : ALUNBRIG IS INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) : 30mg FCT, BRIGATINIB 90mg FCT BRIGATINIB ) , , ( : DOSAGE MODIFICATIONS FOR ADVERSE REACTIONS 3.3 ADVERSE REACTION _ _ SEVERITY* _ _ DOSAGE MODIFICATIONS _ _ HEPATOTOXICITY (ELEVATION OF ALANINE AMINOTRANSFERASE (ALT) OR ASPARTATE AMINOTRANSFERASE (AST)) [SEE WARNINGS AND PRECAUTIONS (6.7)] GRADE 3 OR 4 ELEVATION (GREATER THAN 5 × ULN) OF EITHER ALT OR AST WITH BILIRUBIN LESS THAN OR EQUAL TO 2 × ULN WITHHOLD ALUNBRIG UNTIL RECOVERY TO GRADE 1 OR LESS (LESS THAN OR EQUAL TO 3X ULN) OR TO BASELINE, THEN RESUME ALUNBRIG AT NEXT LOWER DOSE (TABLE 1). GRADE 2 TO 4 ELEVATION (GREATER THAN 3 × ULN) OF ALT OR AST WITH CONCURRENT TOTAL BILIRUBIN ELEVATION GREATER THAN 2 × ULN IN THE ABSENCE OF CHOLESTASIS OR HEMOLYSIS PERMANENTLY DISCONTINUE ALUNBRIG. … . TAKEDA ISRAEL LTD. 25 Efal st., P.O.B 4140, Petach-Tikva 4951125 Tel:+972-3-3733140 Fax (local) : + 972-3-3733150 6.7 HEPATOTOXICITY In ALTA 1L, aspartate aminotransferase (AST) elevations occurred in 72% of patients and Grade 3 or 4 AST elevations occurred in 4.5% of patients. Alanine aminotransferase (ALT) elevations occurred in 52% of patients and Grade 3 or 4 ALT elevations occurred in 5.2% of patients. One patient (0.7%) had a serious adverse reaction of hepatocellular injury. In ALTA, AST elevations occurred in 38% of patients in the 90 mg group and 65% of patients in the 90→180 mg group . ALT elevations occurred in 34% of patients in the 90 mg group and 40% of patients in the 90→180 mg group. Grade 3 or 4 AST elevations occurred in 0.9% of patients in the 90 mg group and did not occur in any patients i n the 90→180 mg group. Grade 3 or 4 ALT elevations did not occur in any patients in the 90 mg Διαβάστε το πλήρες έγγραφο
1 1 NAME OF THE MEDICINAL PRODUCT ALUNBRIG ® 30 MG ALUNBRIG ® 90 MG Brigatinib Film-Coated Tablets, for oral use. 2 THERAPEUTIC INDICATIONS ALUNBRIG is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)- positive metastatic non-small cell lung cancer (NSCLC). 3 DOSAGE AND ADMINISTRATION 3.1 PATIENT SELECTION Select patients for the treatment of metastatic NSCLC with ALUNBRIG based on the presence of ALK positivity in tumor specimens _[see Clinical Studies (13)]_. 3.2 RECOMMENDED DOSAGE The recommended dosage for ALUNBRIG is: • 90 mg orally once daily for the first 7 days; then increase the dose to 180 mg orally once daily. Administer ALUNBRIG until disease progression or unacceptable toxicity. If ALUNBRIG is interrupted for 14 days or longer for reasons other than adverse reactions, resume treatment at 90 mg once daily for 7 days before increasing to the previously tolerated dose. ALUNBRIG may be taken with or without food. Instruct patients to swallow tablets whole. Do not crush or chew tablets, as the tablets are film-coated. If a dose of ALUNBRIG is missed or vomiting occurs after taking a dose, do not administer an additional dose and take the next dose of ALUNBRIG at the scheduled time. 3.3 DOSAGE MODIFICATIONS FOR ADVERSE REACTIONS ALUNBRIG dosage reductions for adverse reactions are summarized in Table 1. TABLE 1: RECOMMENDED ALUNBRIG Dosage reductions DOSAGE DOSAGE REDUCTION FIRST SECOND THIRD 90 mg once daily 60 mg once daily permanently N/A * 180 mg once daily 120 mg once daily 90 mg once daily 60 mg once daily * *Not applicable Once reduced for adverse reactions, do not subsequently increase the dosage of ALUNBRIG. Permanently discontinue ALUNBRIG if patients are unable to tolerate the 60 mg once daily dose. Recommendations for dosage modifications of ALUNBRIG for the management of adverse reactions are provided in Table 2. TABLE 2: RECOMMENDED ALUNBRIG DOSAGE MODIFICATIONS FOR ADVERSE REACTIONS ADVERSE REACTION SEVERITY* DOSAGE MODIFICATIONS 2 Interstitial Lung Dis Διαβάστε το πλήρες έγγραφο